Observational Study of Interstitial Glucose Monitoring With Continuous Glucose Monitoring to Track Patients Treated With Exenatide

Inclusion Criteria: * Male or female (if of child-bearing age must practice appropriate birth control such as tubal ligation, oral contraceptives, abstinence or vasectomized partner during the duration of the study) * Previously diagnosed with type 2 diabetes * Age 21 and older * Treated with metformin, a sulfonylurea, a thiazolidinedione, a combination or metformin and a sulfonylurea, or a combination of metformin and a thiazolidinedione (approved FDA indications) * HbA1c 7.1-11%, unless subject has been using exenatide prior to study; in that case, there is no restriction on HbA1c level. * Willing to give informed consent * Motivated and capable of following the protocol and instructions provided by the healthcare professional * Available for the study on the scheduled visit days * Access to telephone communications Exclusion Criteria: * Under 21 years of age * Pregnancy * Creatinine clearance \<30 ml/min (using MDRD formula) * Known gastrointestinal disease * Without diabetes or known type 1 diabetes * Unable to follow the study protocol * Unable to read and write in English * Allergy to adhesives * Any concomitant medical condition that would likely affect the evaluation of CGM device performance as determined by the investigator such as dermatological conditions or myxedema.